NY-ESO-1 protein expression in primary breast carcinoma and metastases - Correlation with CD8+ T-cell and CD79a+ plasmacytic/B-cell infiltration

International Journal of Cancer

Volumn 120, Issue 11, 2007, Pages 2411-2417

  Theurillat, Jean Philippe ^a   Ingold, Fabienne ^a   Frei, Claudia ^a,c   Zippelius, Alfred ^a   Varga, Zsuzsanna ^a   Seifert, Burkhardt ^a   Chen, Yao Tseng ^b   Jäger, Dirk ^a,c   Knuth, Alexander ^a   Moch, Holger ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

Breast cancer; Cancer testis antigen; Immunohistochemistry; NY ESO 1; Tissue microarray

Indexed keywords

CD79A ANTIGEN; MESSENGER RNA; NY ESO 1 ANTIGEN;

ADOLESCENT; ADULT; AGED; ARTICLE; B LYMPHOCYTE; BREAST CARCINOMA; CANCER RECURRENCE; CD8+ T LYMPHOCYTE; CORRELATION ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; HUMORAL IMMUNITY; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; LYMPH NODE METASTASIS; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MALE; METASTASIS; PLASMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TESTIS; TISSUE MICROARRAY; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD79; ANTIGENS, NEOPLASM; B-LYMPHOCYTES; BREAST NEOPLASMS; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHOCYTES, TUMOR-INFILTRATING; MEMBRANE PROTEINS; MIDDLE AGED; POLYMERASE CHAIN REACTION;

EID: 34247364939     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22376     Document Type: Article

References (27)

1. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:1659-72.
2. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:1673-84.
3. Jager D, Jager E, Knuth A. Vaccination for malignant melanoma: recent developments. Oncology 2001;60:1-7.
4. Jager E, Ringhoffer M, Altmannsberger M, Arand M, Karbach J, Jager D, Oesch F, Knuth A. Immunoselection in vivo: independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int J Cancer 1997;71:142-7.
5. Jager D, Jager E, Knuth A. Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer. J Clin Pathol 2001;54:669-74.
6. Li G, Miles A, Line A, Rees RC. Identification of tumour antigens by serological analysis of cDNA expression cloning. Cancer Immunol Immunother 2004;53:139-43.
7. Zendman AJ, Ruiter DJ, Van Muijen GN. Cancer/testis-associated genes: identification, expression profile, and putative function. J Cell Physiol 2003;194:272-88.
8. Varga Z, Theurillat JP, Filonenko V, Sasse B, Odermatt B, Jungbluth AA, Chen Y-T, Old LJ, Knuth A, Jager D. Preferential nuclear and cytoplasmic NY-BR-1 protein expression in primary breast cancer and lymph node metastases. Clin Cancer Res 2006;12:2745-51.
9. Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev 2002;188:22-32.
10. Mischo A, Kubuschok B, Ertan K, Preuss KD, Romeike B, Regitz E, Schormann C, de BD, Wadle A, Neumann F, Schmidt W, Renner C, et al. Prospective study on the expression of cancer testis genes and antibody responses in 100 consecutive patients with primary breast cancer. Int J Cancer 2006;118:696-703.
11. Sugita Y, Wada H, Fujita S, Nakata T, Sato S, Noguchi Y, Jungbluth AA, Yamaguchi M, Chen YT, Stocken E, Gnjatic S, Williamson B, et al. NY-ESO-1 expression and immunogenicity in malignant and benign breast tumors. Cancer Res 2004;64:2199-204.
12. Gnjatic S, Atanackovic D, Jager E, Matsuo M, Selvakumar A, Altorki NK, Maki RG, Dupont B, Ritter G, Chen YT, Knuth A, Old LJ. Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses. Proc Natl Acad Sci USA 2003;100:8862-7.
13. Jager D, Knuth A. Antibodies and vaccines - hope or illusion? Breast 2005;14:631-5.
14. Ellis IO, Schnitt SJ, Sastre-Garau X, Bussolati G, Tavasolli FA, Eusebi V, Peterse JL, Mukai K, Tabar L, Comelisse CJ, Sasco AJ, Kaaks R, et al. Tumours of the breast. In: Tavassoli FA, Devilee P, eds. Genetics tumours of the breast and the female genital organs. Lyon: IARC, 2003.9-110.
15. Stam NJ, Spits H, Ploegh HL. Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products. J Immunol 1986;137:2299-306.
16. Vitale M, Pelusi G, Taroni B, Gobbi G, Micheloni C, Rezzani R, Donato F, Wang X, Ferrone S. HLA class I antigen down-regulation in primary ovary carcinoma lesions: association with disease stage. Clin Cancer Res 2005;11:67-72.
17. Zippelius A, Gati A, Bartnick T, Walton S, Odermatt B, Jaeger E, Dummer R, Urosevic M, Filonenko V, Osanai K, Moch H, Chen YT, et al. Melanocyte differentiation antigen RAB38/NY-MEL-1 induces frequent antibody responses exclusively in melanoma patients. Cancer Immunol Immunother 2006;23:1-10.
18. van Enden PM. Genes regulating MHC class I processing of antigen. Curr Opin Immunol 1999;11:82-8.
19. Jager E, Jager D, Knuth A. Clinical cancer vaccine trials. Curr Opin Immunol 2002;14:178-82.
20. Seliger B, Maeurer MJ, Ferrone S. Antigen-processing machinery breakdown and tumor growth. Immunol Today 2000;21:455-64.
21. Hicklin DJ, Marincola FM, Ferrone S. HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Mol Med Today 1999;5:178-86.
22. Scanlan MJ, Gout I, Gordon CM, Williamson B, Stockert E, Gure AO, Jager D, Chen YT, Mackay A, O'Hare MJ, Old LJ. Humoral immunity to human breast cancer: antigen definition and quantitative analysis of mRNA expression. Cancer Immun 2001;30:1-4.
23. Jager E, Gnjatic S, Nagata Y, Stockert E, Jager D, Karbach J, Neumann A, Rieckenberg J, Chen YT, Ritter G, Hoffman E, Arand M, et al. Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci USA 2000;97:12198-203.
24. Stockert E, Jager E, Chen YT, Scanlan MJ, Gout I, Karbach J, Arand M, Knuth A, Old LJ. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 1998;187:1349-54.
25. Kurashige T, Noguchi Y, Saika T, Ono T, Nagata Y, Jungbluth A, Ritter G, Chen YT, Stockert E, Tsushima T, Kumon H, Old LJ, et al. Ny-ESO-1 expression and immunogenicity associated with transitional cell carcinoma: correlation with tumor grade. Cancer Res 2001;61:4671-4.
26. Valmori D, Dutoit V, Lienard D, Rimoldi D, Pittet MJ, Champagne P, Ellefsen K, Sahin U, Speiser D, Lejeune F, Cerottini JC, Romero P. Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients. Cancer Res 2002;60:4499-506.
27. Khong HT, Rosenberg SA. Pre-existing immunity to tryrosinase-related protein (TRP)-2, a new TRP-2 isoform, and the NY-ESO-1 melanoma antigen in a patient with a dramatic response to immunotherapy. J Immunol 2002;15:951-6.